Real-World data on HAE drug lanadelumab: does it cut attacks?

NCT ID NCT05469789

Ongoing Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study follows 50 people in the UK with hereditary angioedema (HAE) types I or II who are taking lanadelumab. Researchers will compare the number of HAE attacks in the year before starting the drug to up to two years after. The goal is to see how well the drug works outside of clinical trials, using patient diaries and medical records.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lanadelumab
What this could lead to: If successful, this study could confirm that lanadelumab reduces HAE attacks in everyday clinical practice, supporting its use as a standard treatment.
What could go wrong: This is an observational study with only 50 participants, so results may not apply to all patients. It does not test a new drug or prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary angioedema hereditary angioedema type 1 hereditary angioedema type 2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY ANGIOEDEMA (HAE)

Contacts and locations

Locations

Barts Health NHS Trust

London, England, E1 1BB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.